Aimovig (erenumab-aooe) / Amgen, Novartis - LARVOL DELTA

Therapeutic Potential of Calcitonin Gene-related Peptide Antagonists in Spinal Cord Injury Related Neuropathic Pain: A Case Report (ASRA-FALL 2025) - "The patient was treated with scheduled acetaminophen, pregabalin, and duloxetine. Numerous opioid analgesic regimens were trialed (including oxycodone, tramadol, hydromorphone, and topical buprenorphine), either without significant analgesia or with significant sedation. Given the patient’s history of migraines, erenumab , a once monthly injectable CGRPi , was started."

Case report • Clinical • Anesthesia • CNS Disorders • Migraine • Musculoskeletal Diseases • Neuralgia • Orthopedics • Pain

Impact of Erenumab on Comorbid Depression, Anxiety, and Sleep Quality in Migraine: A Registry for Migraine (REFORM) Study. (PubMed, Eur J Neurol) - "Erenumab treatment is associated with improvement in anxiety, depression, and sleep-related symptoms, specifically in treatment responders. These benefits appear mediated by migraine control rather than direct pharmacological effects."

Journal • CNS Disorders • Depression • Migraine • Mood Disorders • Pain • Psychiatry • Sleep Disorder

Screening Trial for Pain Relief in Schwannomatosis (STARFISH) (clinicaltrials.gov) - P2 | N=40 | Recruiting | Sponsor: Massachusetts General Hospital | Trial primary completion date: Mar 2026 ➔ Nov 2026

Trial primary completion date • Brain Cancer • Pain • Solid Tumor

Multidisciplinary Translational Approach to Investigate Mechanisms Predictors & Prevention of Persistent PTH (clinicaltrials.gov) - P2 | N=6 | Completed | Sponsor: Mayo Clinic | Active, not recruiting ➔ Completed | N=112 ➔ 6

Enrollment change • Trial completion • Pain

Prophylactic Management of Vestibular Migraine: A Systematic Review. (PubMed, Ann Clin Transl Neurol) - "Moderate-quality evidence supports the use of propranolol and topiramate as first-line prophylactic treatments for VM. Emerging data suggest that anti-CGRP agents may be beneficial for refractory cases. Larger, rigorously designed trials are necessary to establish standardized and individualized treatment protocols."

Journal • Review • CNS Disorders • Migraine • Otorhinolaryngology • Pain • Vertigo

Efficacy and tolerability of erenumab for chronic migraine in association with medication overuse: A systematic review and meta-analysis. (PubMed, Headache) - "Erenumab appears effective in reducing migraine frequency and symptomatic medication use among patients with chronic migraine MOH, with an acceptable tolerability profile."

Journal • Retrospective data • Review • CNS Disorders • Constipation • Gastroenterology • Gastrointestinal Disorder • Migraine • Pain

Aimovig: Regulatory submission for pediatric migraine in 2028 or later (Novartis) - Q3 2025 Results

Filing • CNS Disorders • Migraine

The clinical outcome of patients starting monoclonal antibodies anti-CGRP with concomitant migraine preventive treatments. (PubMed, Cephalalgia) - "The analysis was conducted on 555 patients who started galcanezumab (260; 46.8%), erenumab 140 mg (167; 30.0%) or fremanezumab (128; 23.1%). Overall, 13% of patients reported at least one adverse event.ConclusionsOur study confirms that concomitant SPTs at baseline do not influence the clinical outcome of CGRP mAbs after six months of treatment. A progressive withdrawal of SPTs during 12-month anti-CGRP therapy was observed, dissimilar among preventive classes, with persistence of SPTs at T12, mainly in patients with comorbid conditions."

Clinical data • Journal • Observational data • CNS Disorders • Migraine • Pain

Migraine Medication Effects on Urinary Symptoms (clinicaltrials.gov) - P=N/A | N=200 | Enrolling by invitation | Sponsor: The Cleveland Clinic | Trial completion date: May 2026 ➔ Dec 2026 | Trial primary completion date: May 2025 ➔ May 2026

Trial completion date • Trial primary completion date • CNS Disorders • Interstitial Cystitis • Migraine • Musculoskeletal Pain • Overactive Bladder • Pain

Impact of anti-CGRP monoclonal antibodies on treatment satisfaction and quality of life in patients with resistant migraine: a retrospective real-world study. (PubMed, BMC Neurol) - "Patient satisfaction with anti-CGRP mAb therapy was high in this real-world study and correlated with effectiveness measured by the HIT-6 and significantly improved quality of life. Anti-CGRP mAbs are effective and safe for resistant migraine; they have a quick onset of action and provide lasting relief."

HEOR • Journal • Real-world evidence • Retrospective data • CNS Disorders • Migraine • Pain

REAL-WORLD EVIDENCE ON INTRAVENOUS EPTINEZUMAB IN PATIENTS WITH EPISODIC MIGRAINE (WCN 2025) - "They reported in 71% (10/14) prior subcutaneous anti-CGRP mAb use (i.e., fremanezumab, galcanezumab, or erenumab). Our Belgian, real-world data showed that patients with episodic migraine with prior exposure to subcutaneous anti-CGRP mAbs had high overall satisfaction and tolerance after the switch to intravenuous eptinezumab."

Clinical • HEOR • Real-world • Real-world evidence • CNS Disorders • Migraine • Pain

Bridging CGRP mAbs with Gepants: An innovative approach to address the wearing-off phenomenon. (PubMed, Clin Neurol Neurosurg) - "These findings strongly suggest the effectiveness of gepants in managing the wearing-off phenomenon across patients on mAbs. They also underscore the importance of individualized treatment approaches. While CGRP-targeted treatments remain highly effective, ongoing research is essential to optimize long-term use and minimize fluctuations in efficacy, ultimately improving patient reported outcomes."

Journal • CNS Disorders • Migraine • Pain • Psychiatry

Comprehensive assessment of erenumab efficacy in participants with high-frequency episodic migraine with at least one previously failed preventive treatment: The EMBRACE study. (PubMed, Headache) - "Findings from the EMBRACE study demonstrated that treatment with erenumab in patients with high-frequency episodic migraine can provide positive therapeutic effects on ictal burden and pain, with residual migraine attacks tending to be shorter and less painful, with less overall impact."

Journal • CNS Disorders • Migraine • Pain

A randomized, double blind, placebo-controlled pilot study to assess the efficacy of erenumab in individuals with temporomandibular disorder. (PubMed, J Oral Facial Pain Headache) - P2 | "Erenumab was not efficacious in reducing TMD myalgic pain in this phase II trial of 30 subjects with relatively mild pain."

Clinical • Journal • CNS Disorders • Depression • Migraine • Mood Disorders • Musculoskeletal Diseases • Musculoskeletal Pain • Pain • Psychiatry

Patient Adherence and Long-Term Tolerability of Anti-calcitonin Gene-Related Peptide (CGRP) Monoclonal Antibodies in Migraine Prevention: A Systematic Review. (PubMed, Cureus) - "Anti-calcitonin gene-related peptide (CGRP) monoclonal antibodies (mAbs: erenumab, fremanezumab, galcanezumab, and eptinezumab) represent a targeted therapeutic advance, but long-term adherence and safety remain under investigation. Responder rates (≥50% reduction in monthly migraine days) improved from 44% at three months to 64% at 12 months, with network meta-analyses suggesting greater efficacy compared with topiramate and OnabotulinumtoxinA, though direct head-to-head RCTs remain lacking. Overall, anti-CGRP mAbs demonstrate favorable adherence, sustained tolerability, and comparative advantages over conventional therapies, but further research is needed to assess long-term safety beyond 12 months, cost-effectiveness, and use in special populations such as pregnancy."

Journal • Review • CNS Disorders • Constipation • Gastroenterology • Gastrointestinal Disorder • Migraine • Pain

Permanent visual impairment following a Behçet's disease flare while on calcitonin gene-related peptide receptor antagonist therapy: a case report. (PubMed, BMC Ophthalmol) - "We hypothesize that the patient's visual loss was due to secondary ischemia from BD-associated small-vessel vasculitis, potentially exacerbated by CGRP receptor blockade from erenumab, which may have impaired compensatory vasodilation in the optic nerve or retinal circulation. This case represents the first report of permanent bilateral visual impairment associated with CGRP antagonist use in a patient with BD. Recent FDA labeling updates for CGRP-targeting agents now caution against use in patients with preexisting vascular disease, including risk of hypertension and Raynaud's phenomenon. This case underscores the need for heightened caution when prescribing CGRP inhibitors to patients with systemic vasculitic disorders and highlights the importance of further investigation to better define the safety profile of these agents in individuals with underlying vascular disease."

Journal • Cardiovascular • CNS Disorders • Hypertension • Migraine • Ocular Inflammation • Ophthalmology • Pain • Rare Diseases • Rheumatology • Uveitis • Vasculitis

Number Needed to Treat and Cost Per Responder Analysis of Anti-CGRP Monoclonal Antibodies for Migraine Prevention in Adults for Whom Prior Preventive Treatments have Failed. (PubMed, Adv Ther) - "These results show that, for most anti-CGRP mAbs, a low number of participants (< 10) with migraine need to be treated to achieve one person with a ≥ 50% or ≥ 75% reduction in MMDs over Weeks 1-12, with CPR ranging from £4647 (eptinezumab 100 mg) to £21,862 (fremanezumab 675 mg/q)."

Clinical • HEOR • Journal • CNS Disorders • Migraine • Pain

NEW THERAPEUTIC APPROACHES FOR TRIGEMINAL NEURALGIA (IHC 2025) - "On the other hand, erenumab did not show better results than placebo...PRF of the Gasser ganglion combined with dexamethasone and bupivacaine showed greater efficacy in post-herpetic neuralgia, with rapid pain relief and less use of pregabalin and analgesics...Conclusion Although carbamazepine remains the standard treatment, new approaches, such as electroacupuncture and pulsed radiofrequency, have shown good efficacy with a lower incidence of adverse effects. Neurosurgical alternatives, such as microvascular decompression and Gamma Knife, expand the options for refractory cases, reinforcing the importance of individualized approaches to pain control and improving quality of life."

Migraine

Long term persistence of onabotulinumtoxinA versus calcitonin gene-related peptide monoclonal antibodies in new initiators with chronic migraine (IHC 2025) - "Methods This retrospective observational study of adult patients with CM using Merative Marketscan Commercial and Medicare database included new initiators of onabotA or a CGRP mAb (erenumab, fremanezumab, galacanezumab, eptinezumab) who stayed on index treatment from 12 to 24 months. A significantly higher persistence with onabotA continued through 18 months (38.1% vs 29.8%; OR: 0.69 [95% CI: 0.61-0.78]; P<0.001), and 24 months (32.1% vs 23.0%; OR: 0.63 [95% CI: 0.54-0.74]; P<0.001). Conclusion This retrospective claims analysis demonstrated that patients with CM who initiate onabotA are more likely to remain persistent on therapy at all long-term time points for up to 24 months compared with patients with CM who initiate a CGRP mAb."

CNS Disorders • Migraine

Peer-to-Peer Migraine Education in Nigeria: Outcomes from a Pilot Three-Part Lecture Series Targeting Diverse Healthcare Professionals (IHC 2025) - "Knowledge of preventive treatments was low: 10.1% were aware of nutraceuticals, and only 7.8% knew of anti-Calcitonin Gene-Related Peptide therapies, with erenumab only recently introduced in Nigeria (May 2023)...This pilot inspired the development of Africa’s first culturally relevant migraine education and awareness platform— www.migraineoutreach.org. Sustained education, regional collaboration, and digital access are vital to scale migraine care in Africa."

CNS Disorders • Migraine

Super-responders (>75% response rate) to anti-CGRP monoclonal antibodies after one year of treatment: a multicenter, prospective, observational study (IHC 2025) - "Methods This multicenter (n=16), prospective real-life study included all consecutive adults with high-frequency episodic (HFEM: 8-14 days/month) or chronic migraine (CM) who had failed >3 prior preventives and were treated with erenumab, fremanezumab, or galcanezumab for >12 months. While 29.4% were early super-responder, 40.6% became super-responders between months 4 and 12. Ultra-late super-responders exhibit fewer symptoms of peripheral ((pain intensity, pain site, unilateral cranial symptoms) and central (ictal allodynia) sensitization compared to early and late super-responders."

Clinical • Observational data • CNS Disorders • Migraine

POST-TRAUMATIC HEADACHE: CLINICAL IMPACT AND NEW THERAPEUTIC STRATEGIES (IHC 2025) - "Some studies, however, had methodological limitations that prevented definitive conclusions on the use of amitriptyline and prazosin. Conclusion Post-traumatic headache is a multifactorial condition, marked by alterations in neuropeptide pathways (CGRP and PACAP-38) and neurovascular hypersensitivity mediated by ion channels (K_ATP and BKCa). Therapeutic strategies such as rTMS, the use of erenumab, botulinum toxin type A and behavioral interventions, associated with changes in lifestyle and sleep hygiene, have shown significant benefits, highlighting the need for further research to consolidate these approaches in the management of PTSD."

Clinical • CNS Disorders • Migraine • ADCYAP1

Erenumab in treatment of migraine patients with psoriasis – two case reports (IHC 2025) - "Given the suspected association with erenumab, therapy was discontinued and later switched to fremanezumab, a monoclonal antibody targeting CGRP itself rather than its receptor. Although erenumab is generally well tolerated, its receptor-specific mechanism may, in certain individuals, modulate immune pathways in a manner that aggravates pre-existing inflammatory conditions. Further prospective studies are needed to better define the safety profile of CGRP inhibitors, particularly in patients with comorbid immune-mediated diseases."

Case report • Clinical • CNS Disorders • Migraine

Menstrual Migraine Prevention with Anti-CGRP Monoclonal Antibodies: A Meta-Analysis of Randomized Controlled Trials (IHC 2025) - "Anti-CGRP monoclonal antibodies (erenumab and galcanezumab) were associated with a statistically significant reduction in monthly migraine days (MMD) compared to placebo (pooled SMD = −0.53; 95% CI: −1.04 to −0.03; p = 0.05), suggesting a potential clinical benefit, as shown in Figure 1. Conclusion Anti-CGRP monoclonal antibodies demonstrate a potential benefit in preventing menstrually related migraine. Further studies specifically targeting this population could strengthen this evidence."

Retrospective data • CNS Disorders • Migraine

Prescription of monoclonal antibodies against calcitonin gene-related peptide for the prophylaxis of migraine in Austria: a retrospective, longitudinal analysis of nationwide insurance data (IHC 2025) - "Methods Based on the nation-wide database of the Austrian Social Insurances, we included all persons with a dispensation of erenumab, galcanezumab, or fremanezumab from 1 September 2018 to 30 September 2022 and investigated: therapy breaks, switches, the dispensation of triptans, other acute prescription medications, and of other migraine preventatives before, during and after the dispensation of CGRP-Ab, the proportion of days covered. The proportion of days covered was 96 %. Conclusion This first nation-wide pharmacoepidemiologic study showed that within 49 months persistence to CGRP-Ab was excellent, the majority resumed CGRP-Ab soon after a therapy break, and the dispensation of triptans and other preventatives decreased during treatment with CGRP-Ab."

Reimbursement • Retrospective data • US reimbursement • CNS Disorders • Migraine